|Charles River Laboratories Adds Martin Mackay, Ph.D. to Board of Directors|
“Dr. Mackay’s broad experience in drug research, across the discovery
and development spectrum, will enhance the expertise of Charles River’s
Board and play a valuable role as we plan and execute the strategy for
Charles River’s future growth,” said
Dr. Mackay has more than 30 years of experience in drug discovery and
development on a global scale. He was most recently Executive Vice
President, Head of Research and Development at Alexion. Prior to joining
Alexion, Dr. Mackay served as President, Research and Development at
“I have worked extensively with Charles River for many years and have been impressed with the company’s scientific expertise and deep commitment to its clients. I am pleased to join the Board and look forward to contributing to the future success and growth of this recognized global leader in early-stage drug research,” said Dr. Mackay.
Caution Concerning Forward-Looking Statements
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by the use of words such as
“anticipate,” “believe,” “expect,” “intend,” “will,” “may,” “estimate,”
“plan,” “outlook,” and “project,” and other similar expressions that
predict or indicate future events or trends or that are not statements
of historical matters. Forward looking statements include statements in
this press release regarding future demand for drug discovery and
development products and services including the outsourcing of these
services, and the specific contributions of members of Charles River's
Board of Directors. Forward-looking statements are based on Charles
River’s current expectations and beliefs, and involve a number of risks
and uncertainties that are difficult to predict and that could cause
actual results to differ materially from those stated or implied by the
forward-looking statements. A further description of these risks,
uncertainties, and other matters can be found in the Risk Factors
detailed in Charles River's Annual Report on Form 10-K as filed on
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
Charles River Laboratories International, Inc.